Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster
Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster: A Multicenter, Randomized, Prospective Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Jin-Zhu Guo, M.D.
- Phone Number: 008613521115717
- Email: guojinzhu_826@163.com
Study Locations
-
-
-
Beijing, China, 100191
- Recruiting
- Peking University Third Hospital
-
Contact:
- Jinzhu Guo, M.D.
- Phone Number: 008615611963350
- Email: guojinzhu_826@163.com
-
Beijing, China
- Recruiting
- Peking University First Hospital
-
Contact:
- Xiaowen Wang, M.D.
- Phone Number: 008615901254602
- Email: xiaowenpku@126.com
-
Beijing, China
- Recruiting
- Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
-
Contact:
- Dongmei Zhou, M.D.
- Phone Number: 008613811201580
- Email: 52176857@163.com
-
Beijing, China
- Not yet recruiting
- Xuanwu Hospital, Capital Medical University
-
Contact:
- Haiping Zhang, M.D.
- Phone Number: 008613701205765
- Email: zhanghaiping@xwhosp.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥18 years, regardless of gender;
- Signed Informed Consent Form;
Female subjects must not plan for pregnancy or oocyte donation from screening until 1 week after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include:
- Barrier methods: Condom or barrier cap (diaphragm or cervical cap);
- Intrauterine device (IUD) or intrauterine system (IUS);
- Surgical sterilization (bilateral oophorectomy with/without hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner;
- Other investigator-confirmed highly effective physical contraception.
Exclusion Criteria:
- Allergy to brivudine, famciclovir, or penciclovir;
- Current use of fluorouracil agents (e.g., 5-fluorouracil, capecitabine, tegafur, flucytosine);
- Cancer patients currently undergoing chemotherapy;
- Pregnant or lactating women;
- Parkinson's disease;
- Any condition deemed inappropriate for study participation by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Brivudine Group
|
brivudine 125 mg per dose, once daily, 7 days
|
|
Active Comparator: Famciclovir Group
|
orally receive famciclovir at doses adjusted based on creatinine clearance (CrCl), 7 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Day 30 numeric pain rating scale (NPRS)
Time Frame: Day 30
|
Scores range from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable.
Higher scores indicate greater pain intensity.
|
Day 30
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
numeric pain rating scale (NPRS) on Day 3, Day 7, Day 14, Day 90
Time Frame: Day 3, Day 7, Day 14, Day 90
|
Scores range from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable.
Higher scores indicate greater pain intensity.
|
Day 3, Day 7, Day 14, Day 90
|
|
Incidence of PHN
Time Frame: Day 90
|
Incidence of Postherpetic Neuralgia
|
Day 90
|
|
skin lesion on Day 3, Day 7, Day 14, Day 30, Day 90
Time Frame: Day 3, Day 7, Day 14, Day 30, Day 90
|
whether the presence of hemorrhagic bullae, bullae, erosions, or ulcers
|
Day 3, Day 7, Day 14, Day 30, Day 90
|
|
Lesion area on Day 3, Day 7, Day 14, Day 30 and Day 90
Time Frame: Day 3, Day 7, Day 14, Day 30 and Day 90
|
Percentage of body surface area (BSA%) affected by lesions on Day 3, Day 7, Day 14, Day 30 and Day 90
|
Day 3, Day 7, Day 14, Day 30 and Day 90
|
|
cessation of new lesion formation
Time Frame: Day 3, Day 7, Day 14, Day 30 and Day 90
|
whether cessation of new papule/vesicle formation on Day 3, Day 7, Day 14, Day 30 and Day 90
|
Day 3, Day 7, Day 14, Day 30 and Day 90
|
|
complete crusting of all lesions
Time Frame: Day 3, Day 7, Day 14, Day 30 and Day 90
|
whether complete crusting of all lesions Day 3, Day 7, Day 14, Day 30 and Day 90
|
Day 3, Day 7, Day 14, Day 30 and Day 90
|
|
Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From baseline to Day 30
|
Adverse Events (AEs) and Serious Adverse Events (SAEs) in 30 days
|
From baseline to Day 30
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Varicella Zoster Virus Infection
- Neurologic Manifestations
- Infections
- Virus Diseases
- DNA Virus Infections
- Herpesviridae Infections
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain
- Herpes Zoster
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Purines
- Adenine
- Famciclovir
- brivudine
Other Study ID Numbers
Other Study ID Numbers
- M20250600
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.